Imaging kidney disease using noninvasive techniques to detect complement biomarkers
Noninvasive molecular imaging of complement biomarkers in kidney disease
['FUNDING_CAREER'] · UNIVERSITY OF COLORADO DENVER · NIH-10984320
This study is testing a new way to take pictures of important proteins in the kidneys that can help us understand kidney disease better, and it’s designed for patients who want to explore improved ways to monitor and treat their kidney conditions.
Quick facts
| Phase | ['FUNDING_CAREER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF COLORADO DENVER (nih funded) |
| Locations | 1 site (Aurora, UNITED STATES) |
| Trial ID | NIH-10984320 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a new imaging technique to visualize and measure complement proteins in the kidneys, which are important in kidney disease. The approach involves using a specialized imaging method called Immuno-PET, which allows for noninvasive observation of these biomarkers in patients. By studying the molecular changes associated with complement activation, researchers aim to improve the understanding of kidney disease and enhance diagnostic capabilities. Patients may benefit from this innovative tool that could lead to better monitoring and treatment options for kidney conditions.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with kidney disease who may have complement activation as part of their condition.
Not a fit: Patients with kidney disease not associated with complement activation or those without a diagnosis of kidney disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved diagnostic methods for kidney disease, allowing for earlier detection and better-targeted treatments.
How similar studies have performed: Previous research has shown promise in using molecular imaging techniques for other diseases, suggesting potential success for this novel approach in kidney disease.
Where this research is happening
Aurora, UNITED STATES
- UNIVERSITY OF COLORADO DENVER — Aurora, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: POPPELAARS, FELIX — UNIVERSITY OF COLORADO DENVER
- Study coordinator: POPPELAARS, FELIX
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Bright Disease